-
Je něco špatně v tomto záznamu ?
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
RL. Coleman, D. Lorusso, C. Gennigens, A. González-Martín, L. Randall, D. Cibula, B. Lund, L. Woelber, S. Pignata, F. Forget, A. Redondo, SD. Vindeløv, M. Chen, JR. Harris, M. Smith, LV. Nicacio, MSL. Teng, A. Laenen, R. Rangwala, L. Manso, M....
Jazyk angličtina Země Velká Británie
Typ dokumentu klinické zkoušky, fáze II, časopisecké články, multicentrická studie, práce podpořená grantem
NLK
ProQuest Central
od 2000-09-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest)
od 2000-09-01 do Před 2 měsíci
Health & Medicine (ProQuest)
od 2000-09-01 do Před 2 měsíci
Public Health Database (ProQuest)
od 2000-09-01 do Před 2 měsíci
- MeSH
- dospělí MeSH
- humanizované monoklonální protilátky škodlivé účinky terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- lokální recidiva nádoru farmakoterapie mortalita MeSH
- metastázy nádorů MeSH
- nádory děložního čípku farmakoterapie mortalita patologie MeSH
- oligopeptidy škodlivé účinky terapeutické užití MeSH
- tkáňový faktor analýza MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze II MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
BACKGROUND: Few effective second-line treatments exist for women with recurrent or metastatic cervical cancer. Accordingly, we aimed to evaluate the efficacy and safety of tisotumab vedotin, a tissue factor-directed antibody-drug conjugate, in this patient population. METHODS: This multicentre, open-label, single-arm, phase 2 study was done across 35 academic centres, hospitals, and community practices in Europe and the USA. The study included patients aged 18 years or older who had recurrent or metastatic squamous cell, adenocarcinoma, or adenosquamous cervical cancer; disease progression on or after doublet chemotherapy with bevacizumab (if eligible by local standards); who had received two or fewer previous systemic regimens for recurrent or metastatic disease; had measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1); and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients received 2·0 mg/kg (up to a maximum of 200 mg) tisotumab vedotin intravenously once every 3 weeks until disease progression (determined by the independent review committee) or unacceptable toxicity. The primary endpoint was confirmed objective response rate based on RECIST (version 1.1), as assessed by the independent review committee. Activity and safety analyses were done in patients who received at least one dose of the drug. This study is ongoing with recruitment completed and is registered with ClinicalTrials.gov, NCT03438396. FINDINGS: 102 patients were enrolled between June 12, 2018, and April 11, 2019; 101 patients received at least one dose of tisotumab vedotin. Median follow-up at the time of analysis was 10·0 months (IQR 6·1-13·0). The confirmed objective response rate was 24% (95% CI 16-33), with seven (7%) complete responses and 17 (17%) partial responses. The most common treatment-related adverse events included alopecia (38 [38%] of 101 patients), epistaxis (30 [30%]), nausea (27 [27%]), conjunctivitis (26 [26%]), fatigue (26 [26%]), and dry eye (23 [23%]). Grade 3 or worse treatment-related adverse events were reported in 28 (28%) patients and included neutropenia (three [3%] patients), fatigue (two [2%]), ulcerative keratitis (two [2%]), and peripheral neuropathies (two [2%] each with sensory, motor, sensorimotor, and neuropathy peripheral). Serious treatment-related adverse events occurred in 13 (13%) patients, the most common of which included peripheral sensorimotor neuropathy (two [2%] patients) and pyrexia (two [2%]). One death due to septic shock was considered by the investigator to be related to therapy. Three deaths unrelated to treatment were reported, including one case of ileus and two unknown causes. INTERPRETATION: Tisotumab vedotin showed clinically meaningful and durable antitumour activity with a manageable and tolerable safety profile in women with previously treated recurrent or metastatic cervical cancer. Given the poor prognosis for this patient population and the low activity of current therapies in this setting, tisotumab vedotin, if approved, would represent a new treatment for women with recurrent or metastatic cervical cancer. FUNDING: Genmab, Seagen, Gynaecologic Oncology Group, and European Network of Gynaecological Oncological Trial Groups.
Aalborg University Hospital Aalborg Denmark
Centre Hospitalier de l'Ardenne Libramont Belgium
Department of Medical Oncology Centre Hospitalier Universitaire de Liège Liège Belgium
Hospital Universitario 12 de Octubre Madrid Spain
Massey Cancer Center Virginia Commonwealth University Richmond VA USA
Rigshospitalet Copenhagen University Hospital Copenhagen Denmark
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21018712
- 003
- CZ-PrNML
- 005
- 20210830100310.0
- 007
- ta
- 008
- 210728s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S1470-2045(21)00056-5 $2 doi
- 035 __
- $a (PubMed)33845034
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Coleman, Robert L $u US Oncology Research, The Woodlands, TX, USA. Electronic address: rcoleman@gog.org
- 245 10
- $a Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study / $c RL. Coleman, D. Lorusso, C. Gennigens, A. González-Martín, L. Randall, D. Cibula, B. Lund, L. Woelber, S. Pignata, F. Forget, A. Redondo, SD. Vindeløv, M. Chen, JR. Harris, M. Smith, LV. Nicacio, MSL. Teng, A. Laenen, R. Rangwala, L. Manso, M. Mirza, BJ. Monk, I. Vergote, innovaTV 204/GOG-3023/ENGOT-cx6 Collaborators
- 520 9_
- $a BACKGROUND: Few effective second-line treatments exist for women with recurrent or metastatic cervical cancer. Accordingly, we aimed to evaluate the efficacy and safety of tisotumab vedotin, a tissue factor-directed antibody-drug conjugate, in this patient population. METHODS: This multicentre, open-label, single-arm, phase 2 study was done across 35 academic centres, hospitals, and community practices in Europe and the USA. The study included patients aged 18 years or older who had recurrent or metastatic squamous cell, adenocarcinoma, or adenosquamous cervical cancer; disease progression on or after doublet chemotherapy with bevacizumab (if eligible by local standards); who had received two or fewer previous systemic regimens for recurrent or metastatic disease; had measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1); and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients received 2·0 mg/kg (up to a maximum of 200 mg) tisotumab vedotin intravenously once every 3 weeks until disease progression (determined by the independent review committee) or unacceptable toxicity. The primary endpoint was confirmed objective response rate based on RECIST (version 1.1), as assessed by the independent review committee. Activity and safety analyses were done in patients who received at least one dose of the drug. This study is ongoing with recruitment completed and is registered with ClinicalTrials.gov, NCT03438396. FINDINGS: 102 patients were enrolled between June 12, 2018, and April 11, 2019; 101 patients received at least one dose of tisotumab vedotin. Median follow-up at the time of analysis was 10·0 months (IQR 6·1-13·0). The confirmed objective response rate was 24% (95% CI 16-33), with seven (7%) complete responses and 17 (17%) partial responses. The most common treatment-related adverse events included alopecia (38 [38%] of 101 patients), epistaxis (30 [30%]), nausea (27 [27%]), conjunctivitis (26 [26%]), fatigue (26 [26%]), and dry eye (23 [23%]). Grade 3 or worse treatment-related adverse events were reported in 28 (28%) patients and included neutropenia (three [3%] patients), fatigue (two [2%]), ulcerative keratitis (two [2%]), and peripheral neuropathies (two [2%] each with sensory, motor, sensorimotor, and neuropathy peripheral). Serious treatment-related adverse events occurred in 13 (13%) patients, the most common of which included peripheral sensorimotor neuropathy (two [2%] patients) and pyrexia (two [2%]). One death due to septic shock was considered by the investigator to be related to therapy. Three deaths unrelated to treatment were reported, including one case of ileus and two unknown causes. INTERPRETATION: Tisotumab vedotin showed clinically meaningful and durable antitumour activity with a manageable and tolerable safety profile in women with previously treated recurrent or metastatic cervical cancer. Given the poor prognosis for this patient population and the low activity of current therapies in this setting, tisotumab vedotin, if approved, would represent a new treatment for women with recurrent or metastatic cervical cancer. FUNDING: Genmab, Seagen, Gynaecologic Oncology Group, and European Network of Gynaecological Oncological Trial Groups.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a humanizované monoklonální protilátky $x škodlivé účinky $x terapeutické užití $7 D061067
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a metastázy nádorů $7 D009362
- 650 _2
- $a lokální recidiva nádoru $x farmakoterapie $x mortalita $7 D009364
- 650 _2
- $a oligopeptidy $x škodlivé účinky $x terapeutické užití $7 D009842
- 650 _2
- $a tkáňový faktor $x analýza $7 D013925
- 650 _2
- $a nádory děložního čípku $x farmakoterapie $x mortalita $x patologie $7 D002583
- 655 _2
- $a klinické zkoušky, fáze II $7 D017427
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Lorusso, Domenica $u Multicentre Italian Trials in Ovarian Cancer and Gynaecological Malignancies Group and Scientific Directorate and Department of Women and Child Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- 700 1_
- $a Gennigens, Christine $u Department of Medical Oncology, Centre Hospitalier Universitaire de Liège, Liège, Belgium
- 700 1_
- $a González-Martín, Antonio $u Grupo Español de Investigación en Cáncer de Ovario and Department of Medical Oncology, Clínica Universidad de Navarra, Madrid, Spain
- 700 1_
- $a Randall, Leslie $u Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA
- 700 1_
- $a Cibula, David $u Central and Eastern European Gynecologic Oncology Group and Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Lund, Bente $u Aalborg University Hospital, Aalborg, Denmark
- 700 1_
- $a Woelber, Linn $u Arbeitsgemeinschaft Gynäkologische Onkologie Study Group and University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 700 1_
- $a Pignata, Sandro $u Multicentre Italian Trials in Ovarian Cancer and Gynaecological Malignancies Group and Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione G Pascale" IRCCS, Naples, Italy
- 700 1_
- $a Forget, Frederic $u Centre Hospitalier de l'Ardenne, Libramont, Belgium
- 700 1_
- $a Redondo, Andrés $u Grupo Español de Investigación en Cáncer de Ovario and Hospital Universitario La Paz-IdiPAZ, Madrid, Spain
- 700 1_
- $a Vindeløv, Signe Diness $u Genmab, Copenhagen, Denmark
- 700 1_
- $a Chen, Menghui $u Genmab US, Princeton, NJ, USA
- 700 1_
- $a Harris, Jeffrey R $u Genmab US, Princeton, NJ, USA
- 700 1_
- $a Smith, Margaret $u Genmab US, Princeton, NJ, USA
- 700 1_
- $a Nicacio, Leonardo Viana $u Seagen, Bothell, WA, USA
- 700 1_
- $a Teng, Melinda S L $u Seagen, Bothell, WA, USA
- 700 1_
- $a Laenen, Annouschka $u Belgium and Luxembourg Gynaecological Oncology Group and University of Leuven, Leuven Cancer Institute, Leuven, Belgium
- 700 1_
- $a Rangwala, Reshma $u Genmab US, Princeton, NJ, USA
- 700 1_
- $a Manso, Luis $u Hospital Universitario 12 de Octubre, Madrid, Spain
- 700 1_
- $a Mirza, Mansoor $u Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark
- 700 1_
- $a Monk, Bradley J $u Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ, USA
- 700 1_
- $a Vergote, Ignace $u Belgium and Luxembourg Gynaecological Oncology Group and University of Leuven, Leuven Cancer Institute, Leuven, Belgium
- 710 2_
- $a innovaTV 204/GOG-3023/ENGOT-cx6 Collaborators
- 773 0_
- $w MED00011558 $t The Lancet. Oncology $x 1474-5488 $g Roč. 22, č. 5 (2021), s. 609-619
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33845034 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830100311 $b ABA008
- 999 __
- $a ok $b bmc $g 1689726 $s 1139158
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 22 $c 5 $d 609-619 $e 20210409 $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
- LZP __
- $a Pubmed-20210728
